

Correlation Between Serum Neopterin And Response To Treatment of chronic Hepatitis C Virus Infection

Thesis

Submitted for Partial Fulfillment of Master Degree
in Internal Medicine

By

Essam Lotfy Abd-Elhamed Eid

M.B, B.Ch

Alexandria University

Under Supervision of

Prof. Dr / Rawia Abd El-Salam Ibrahim Elfiky

Professor of Internal Medicine

Faculty of Medicine – Ain Shams University

Prof. Dr/ Noha Abd El Razek El Nakeeb

Professor of Internal Medicine

Faculty of Medicine – Ain Shams University

Dr/ Mohamed Lotfy Soliman

Lecturer of Internal Medicine

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2016



وَأَنْزَلَ اللَّهُ عَلَيْكَ
الْكِتَابَ وَالْحِكْمَةَ
وَعَلَّمَكَ مَا لَمْ تَكُنْ
تَعْلَمُ وَكَانَ فَضْلُ
اللَّهِ عَلَيْكَ عَظِيمًا

صدق الله العظيم □

□ سورة النساء الآية (١١٣)



Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest gratitude and thanks to **Prof. Dr / Rawia Abd El-Salam Ibrahim Elfiky**, Professor of Internal Medicine, Faculty of Medicine – Ain Shams University, for her constructive criticism, unlimited help and giving me the privilege to work under her supervision.*

*My most sincere gratitude is also extended to **Prof. Dr/ Noha Abd El Razek El Nakeeb**, Professor of Internal Medicine, Faculty of Medicine – Ain Shams University, for her enthusiastic help, continuous supervision, guidance and support throughout this work.*

*Words fail to express my appreciation to **Dr/ Mohamed Lotfy Soliman**, Lecturer of Internal Medicine, Faculty of Medicine – Ain Shams University, for the efforts and time he has devoted to accomplish this work.*

*Last but not least, I can't forget to thank all members of my Family, especially my **Parents** and my **Wife**, for pushing me forward in every step in the journey of my life.*



List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables.....	vi
List of Figures	ix
Introduction	1
Aim of the Work.....	3
Review of Literature	
Hepatitis C Virus	4
Neopterin	91
Patients and Methods.....	109
Results.....	115
Discussion	130
Summary	144
Recommendations	147
References	148
Arabic Summary	—

List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
AASLD	: American Association for the Study of Liver Disease
ADV	: Adefovir dipivoxil
AFP	: Alpha Fetoprotein
AHA	: Autoimmune-hemolytic anemia
AHC	: Acute Hepatitis C
Alb-IFN	: Albumin interferon
ALT	: Alanine aminotransferase
ANA	: Antinuclear antibodies
ARF	: Alternate Reading Frame
ASH	: Alcoholic steatohepatitis
AST	: Aspartate aminotransferase
b-DNA	: Branched DNA
BID	: Twice-a-day
BMI	: BodyMass Index
BOC	: Boceprevir
BUN	: Blood Urea Nitrogen
CBC	: Complete Blood Count
cccDNA	: Covalently closed circular DNA
CCG	: Cysteine- Cysteine-Glycine
CD4	: CD81 Cluster of differentiation 4 and 81
CDC	: Center for Disease Control and Prevention, USA
cEVR	: Complete early virological response
CHC	: Chronic hepatitis C

List of Abbreviations *(Cont.)*

<i>Abbr.</i>	<i>Full-term</i>
CIFN	: Consensus interferon
CNI	: Calcineurin inhibitors
CP	: Child-Pugh
CPT	: Child-Pugh-Turcotte
DAAs	: Directly acting antivirals
DM	: Diabetes Mellitus
DNA	: Deoxy ribonucleic acid
E1&E2	: Envelope protein 1 and 2
EASL	: European Association for the Study of the Liver
EBV	: Epstein-Barr virus
ECG	: Electrocardiogram
EHM	: Extrahepatic manifestation
EIA	: Enzyme Immunoassay
ELISA	: Enzyme linked immunosorbent assay
EMA	: European Medicines Agency
ER	: Endoplasmic reticulum
ERC	: Endoscopic retrograde cholangiography
eRVR	: Extended rapid virological response
ETR	: End of Treatment Response
ETV	: Entecavir
EVL	: Everolimus
EVR	: Early virologic response
EVR	: Early Virological Response
F	: Frame shift

List of Abbreviations (Cont.)

<i>Abbr.</i>	<i>Full-term</i>
GFR	: Glomerular filtration rate
GGT	: Gamma Glutamyl Transpeptidase
GH	: Growth hormone
GM-CSF	: Granulocyte macrophage colony stimulating factor
GN	: Glomerulonephritis
GTP	: Guanosine Triphosphate
HAART	: Highly Active Antiretroviral Therapy
HALT-C	: Hepatic C Antiviral Long term Treatment Against Cirrohsis
HBcAg	: Hepatitis B core antigen
HBeAg	: Hepatitis B early antigen
HBsAg	: Hepatitis B surface antigen
HBV	: Hepatitis B virus
HCC	: Hepatocellular carcinoma
HCV Abs	: Hepatitis C virus antibodies
HCV RNA	: Riboneucleic acid of hepatitis C virus
HCV	: Hepatitis C virus
Hgb	: Hemoglobin
HIV	: Human immunodeficiency virus
HRS	: Hepatorenal syndrome
I.M	: Intramuscular
IASL	: International Association for the Study of the Liver
IFN a	: Interferon a
IFNα	: Interferon Alfa
IGF-1	: Insulin growth factor-1

List of Abbreviations *(Cont.)*

<i>Abbr.</i>	<i>Full-term</i>
IgM	: Immunoglobulin M
INR	: International normalised ratio
IPF	: Idiopathic pulmonary fibrosis
ISDR	: Interferon- α Sensitivity Determining Region
ITP	: Immune thrombocytopenic purpura
IU	: International Unit
LAM	: Lamivudine
LDL	: Low density lipoproteins
LDLT	: Living donor liver transplantation
LdT	: Telbivudine
LEL	: Large Extracellular Loop
LPS	: Lipopolysaccharide
LTx	: Liver transplantation
MELD	: Model for End-Stage Liver Disease
MMWR	: Morbidity and Mortality Weekly Report
MPGN	: Membranoproliferative glomerulonephritis
NASBA	: Nucleic acid sequence based amplification
NASH	: Non-alcoholic steatohepatitis
NHL	: Non-Hodgkin lymphoma
NIH	: National Institute of Health
NNI	: Non-nucleoside inhibitors
NPV	: Negative Predictive Value
NS	: Non-Structural protein

List of Abbreviations (Cont.)

<i>Abbr.</i>	<i>Full-term</i>
NS2,NS3, NS4,NS5	Non Structural proteins 2, 3, 4, 5
NTR	: Non-translated regions
P7	: Protein 7
PCR	: Polymerase chain reaction
PCT	: Porphyria cutanea tarda
PDGF	: Platelet-derived growth factor
PEG-IFN	: Pegylated interferon
PPV	: Positive Predictive Value
PT	: Prothrombin time
QD	: Once-a-day
QW	: Once-a-week
RBCs	: Red Blood Cells
RBV	: Ribavirin
RF	: Rheumatoid factor
RIBA	: Recombinant ImmunoBlot Assay
RNA	: Ribonucleic acid
RT-PCR	: Real time polymerase chain reaction
RVR	: Rapid virologic response
RVR	: Rapid Virological Response
S.C	: Subcutaneous
SD	: Standard Deviation
SEL	: Small Extracellular Loop
SOF	: Sofosbuvir
SRL	: Sirolimus

List of Abbreviations *(Cont.)*

<i>Abbr.</i>	<i>Full-term</i>
SSRI	: Serotonin reuptake inhibitor
SVR	: Sustained virologic response
TDF	: Tenofovir disoproxil fumarate
TGF-β	: Transforming growth factor β
TID	: Three times a day
TLV	: Telaprevir
TMA	: Transcription-Mediated Amplification
TSH	: Thyroid-Stimulating Hormone
VLDL	: very low-density lipoproteins
WBCs	: White Blood Cells
WHO	: World Health Organization
Wk	: Week

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Extrahepatic manifestations of chronic hepatitis C infection	20
Table (2):	Types of cryoglobulinemia	21
Table (3):	Child-Pugh classification of severity of liver disease.....	24
Table (4):	Serum-based tests recommended in the clinical practice for the detection of significant fibrosis	32
Table (5):	Approved HCV DAAs in Europe in 2016 and ribavirin.....	36
Table (6):	Relevant definitions for HCV treatment.....	37
Table (7):	Interferon-ribavirin drug information	44
Table (8):	Common adverse events during therapy with peg-interferon α -2b or -2a plus ribavirin.....	46
Table (9):	Incidence of most reported IFN α -induced psychiatric side effects.....	49
Table (10):	Guidelines for adjusting therapy for CBC changes.....	50
Table (11):	Adverse event profile associated with telaprevir and boceprevir in therapy-naïve patients in clinical studies	63
Table (12):	Adverse Events (All Grades and without Regard to Causality) Reported in $\geq 15\%$ of Subjects with HCV in Any Treatment Arm	66

Table (13): Potentially Significant Drug Interactions: Alteration in Dosage or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interactiona.....	67
Table (14): Approved HCV drugs in the	69
Table (15): Treatment recommendations.....	70
Table (16): Treatment recommendations (for HCV- monoinfected or HCV/HIV coinfectd patients with chronic hepatitis C with compensated (Child-Pugh A) cirrhosis, including treatment-naïve patients and patients who failed on a treatment based on PagIFN- α and ribavirin (RBV).....	71
Table (17): Comparison between all groups as regards gender.....	112
Table (18): Comparison between all groups as regards age.....	113
Table (19): Baseline of laboratory investigations.	114
Table (20): Comparison between patients and control groups regarding abdominal ultrasonography..	116
Table (21): Baseline Liver Biopsy Activity and fibrosis according to metavir score.....	117
Table (22): Laboratory investigations after 12 weeks.	117
Table (23): Comparison between baseline of TLC and at week 12 in Early virological Responder and Null responder.....	118
Table (24): Comparison between baseline of Neut and at week 12 in Early virological Responder and Null responder.....	119

Table (25): Comparison between baseline of haemoglobin concentration at week 12 in Early virological Responder and Null responder.....	120
Table (26): Comparison between baseline of PLT and at week 12 in Early virological Responder and Null responder.....	121
Table (27): Comparison between baseline of ALT and at week 12 in Early virological Responder and Null responder.....	122
Table (28): Comparison between baseline of PCR and at week 12 in Early virological Responder and Null responder.....	123
Table (29): Comparison between baseline of Neopterin and at week 12 in Early virological Responder and Null responder.....	124
Table (30): Correlation between serum neopterin and different parameters in the studied groups.....	126
Table (31): Roc curve between patient and control group as regards neopterin.....	127
Table (32): ROC curve between Early virological Responder and Null responder.....	129

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Hepatitis C virus (HCV) model structure and genome organization.....	5
Figure (2):	HCV-coding proteins and their representative direct-acting antiviral agents (DAAs).....	7
Figure (3):	Countries by the majority genotype found across all associated studies	9
Figure (4):	Natural History of HCV Infection	16
Figure (5):	Schematic representation of EHM categories.....	21
Figure (6):	Graphic display of virological responses, RVR, rapid virological response	43
Figure (7):	Time course of interferon-associated adverse events	47
Figure (8):	Genomic organization of HCV	54
Figure (9):	Molecular structure of the HCV NS3/4A protease	54
Figure (10):	Structure of the HCV NS5B RNA polymerase and binding sites	57
Figure (11):	Biosynthesis of neopterin derivatives in human monocytes/macrophages.	89
Figure (12):	Molecular structure of Neopterin.....	91
Figure (13):	Comparison between baseline of TLC and at week 12 in Early virological Responder and Null responder.....	118

Figure (14): Comparison between baseline of Neut and at week 12 in Early virological Responder and Null responder.....	119
Figure (15): Comparison between baseline of HB% and at week 12 in Early virological Responder and Null responder.....	120
Figure (16): Comparison between baseline of PLT and at week 12 in Early virological Responder and Null responder.	121
Figure (17): Comparison between baseline of ALT and at week 12 in Early virological Responder and Null responder.....	122
Figure (18): Comparison between baseline of PCR and at week 12 in Early virological Responder and Null responder.....	123
Figure (19): Comparison between baseline of Neopterin and at week 12 in Early virological Responder and Null responder.	125
Figure (20): AUC (area under curve) for neopterin to predict HCV diseased patien.....	127
Figure (21): The cutoff value of neopterin to predict sensitivity and specificity of neopterin level in between HCV diseased patients and control.	128
Figure (22): The AUC (area under curve) for neopterin to predict HCV disease from neopterin levels of the patients.....	128
Figure (23): The cutoff value of neopterin to predict the difference between EVR and null responder sensitivity and specificity from neopterin levels of HCV diseased patients.	129